# Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide

> **NCT00125606** · PHASE3 · TERMINATED · sponsor: **University Hospital Muenster** · enrollment: 30 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** conditioning for allogeneic HSCT

## Key facts

- **NCT ID:** NCT00125606
- **Lead sponsor:** University Hospital Muenster
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** insufficient patient recruitement
- **Last updated:** 2012-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125606, "Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00125606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*